HOME >> MEDICINE >> NEWS
NIH funds new brain imaging center at San Francisco VA Medical Center

A $2 million grant from the National Institutes of Health to use towards the purchase of the latest in brain-imaging equipment has been received by the San Francisco VA Medical Center.

The new high-field MRI/MR spectroscopy system will be the centerpiece of a new center for the imaging of neurodegenerative diseases, including Alzheimer's disease, epilepsy, post-traumatic stress disorder (PTSD), Gulf War syndrome and more, said Michael Weiner, MD, who will serve as the new center's director.

"This is going to be the only high-field system in the world that is focused exclusively on neurodegenerative diseases," said Weiner, who is director of the Magnetic Resonance Unit at San Francisco Veterans Affairs Medical Center and a professor of radiology, medicine, psychiatry and neurology at the University of California, San Francisco.

"This system will allow us to see smaller structures in the brain," Weiner said. The system measures different chemicals in the brain non-invasively and without the use of dyes or tracers. For example, it can measure the levels of glutamate, the neurotransmitter suspected of playing a role in Alzheimer's disease, amytropic lateral sclerosis (ALS or Lou Geherig's disease), and Parkinson's disease. "This is a unique resource," Weiner said.

The 4 Tesla high-field MRI/MR spectroscopy system is three times more powerful than the standard type of MRI in common use today. It will be used in particular for the early detection of Alzheimers--the most common disease of aging veterans and the elderly in general. The system will also be used to monitor the effectiveness of treatment of the disease.

In addition to patient treatment, the center will conduct research expected to advance the field significantly by testing the newest drug treatments developed specifically for Alzheimer's and other neurodegenerative disorders.

The $2 million grant comes from NIH's highly competitive Research Resources fund and w
'"/>

Contact: Camille Mojica Rey
cmrey@pubaff.ucsf.edu
415-221-4810 x5100
University of California - San Francisco
21-Nov-2002


Page: 1 2

Related medicine news :

1. Can you read my mind? W.M. Keck Foundation funds innovative brain research at Carnegie Mellon
2. Rices CNST awards Smalley/Curl funds for innovation
3. Entrepreneurism Center at UC San Diego funds commercialization of lung, shock, other devices
4. Federal funds given for regenerative medicine center
5. The NIH funds network to study drug-induced liver injury (DILIN)
6. NIH funds seven science education partnership awards
7. $25 million funds health promotion studies at UT School of Public Health
8. NIH funds project to help senior citizens access health care
9. NCCAM funds Developmental Centers for Research on Complementary and Alternative Medicine
10. NCCAM funds Centers of Excellence for Research on Complementary and Alternative Medicine
11. NIH funds two UCSD scientists to venture deep into human genome

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: NIH funds new brain imaging center San Francisco Medical Center

(Date:7/30/2014)... New York City, NY (PRWEB) July 30, 2014 ... Memorial & Museum at Ground Zero, the Ground Zero Museum ... confusion in recent tour bookings. Says the Museum Workshop's Carole ... tour and museum on all the major travel sites who ... Our description is now crystal clear as to what we ...
(Date:7/30/2014)... NY, July 30, 2014We have pills to ease pain, to ... conditions, and to enhance our sexual and athletic prowess. Why ... and could we benefit from taking fewer pills? This provocative ... The Role and Fantasy of Pills in Modern Medicine ," ... , a peer-reviewed publication from Mary Ann Liebert, Inc., publishers. ...
(Date:7/30/2014)... WEDNESDAY, July 30, 2014 (HealthDay News) -- Medical costs ... States are more than $32 billion each year, according ... Control and Prevention. The yearly financial toll of ... to reach an estimated $49 billion by 2020. ... for COPD, which provide state public health practitioners with ...
(Date:7/30/2014)... in Manchester have identified a protein that could help ... a treatment that makes radiotherapy more effective, according to ... Cancer (BJC). , The team from The University ... that patients whose bladder tumour had high levels of ... from having carbogen oxygen mixed with carbon dioxide ...
(Date:7/30/2014)... Up to 20 percent of Parkinson,s disease (PD) ... but largely unrecognized challenge: the occurrence of impulse ... behavior, eating, or spending. Yet the presence of ... complicate treatment options. A team of investigators from ... of Pennsylvania and the Parkinson,s Disease Research, Education ...
Breaking Medicine News(10 mins):Health News:Despite Some Confusion over 9/11 Memorial Opening, Kid-Friendly Ground Zero Museum Workshop on 14th Street Continues It's Mission 2Health News:Despite Some Confusion over 9/11 Memorial Opening, Kid-Friendly Ground Zero Museum Workshop on 14th Street Continues It's Mission 3Health News:Despite Some Confusion over 9/11 Memorial Opening, Kid-Friendly Ground Zero Museum Workshop on 14th Street Continues It's Mission 4Health News:Despite Some Confusion over 9/11 Memorial Opening, Kid-Friendly Ground Zero Museum Workshop on 14th Street Continues It's Mission 5Health News:Annual COPD Costs To Hit $49 Billion by 2020: CDC 2Health News:Scientists pinpoint bladder cancer patients who could benefit from 'tumor-softening' treatment 2Health News:Penn researchers: Naltrexone may diminish impulse control disorders in Parkinson's disease patients 2
(Date:7/30/2014)... 30, 2014 Stryker brand ambassadors Fred Funk ... 3M Championship Champions Tour event near Minneapolis, MN ... Blaine . Stryker is the official joint replacement products company ... Friday, August 1 st through Sunday, August 3 rd , ... on-site joint health destination located in the Pioneer Press Expo tent ...
(Date:7/30/2014)... PARIS , July 30, 2014 /PRNewswire/ ... Sanofi (EURONEXT: SAN and NYSE: SNY ) ... of alirocumab in people with hypercholesterolemia met their primary ... in low-density lipoprotein cholesterol (LDL-C) at 24 weeks compared ... monoclonal antibody targeting PCSK9 (proprotein convertase subtilisin/kexin type 9). ...
(Date:7/30/2014)... and SAN DIEGO , July 30, 2014 ... ARNA ) announced today that an article based on post-hoc ... entitled, "Early Weight Loss While on Lorcaserin, Diet, and Exercise ... published in the online issue of Obesity , the ... of these analyses was to identify whether there is an ...
Breaking Medicine Technology:Stryker Brand Ambassadors Fred Funk And Hal Sutton Set To Play At 3M Championship 2Stryker Brand Ambassadors Fred Funk And Hal Sutton Set To Play At 3M Championship 3Stryker Brand Ambassadors Fred Funk And Hal Sutton Set To Play At 3M Championship 4Stryker Brand Ambassadors Fred Funk And Hal Sutton Set To Play At 3M Championship 5Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 2Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 3Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 4Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 5Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 6Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 7Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 8Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 2Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 3Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 4Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 5Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 6Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 7
Cached News: